67259-62-5

Basic information

• Product Name: 4-(4-METHOXYPHENYL)PIPERIDINE
• Synonyms: 4-(4-METHOXYPHENYL)PIPERIDINE;Piperidine, 4-(4-methoxyphenyl)-
• CAS NO: 67259-62-5
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.27
• Mol File: 67259-62-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 304℃
• Flash Point: 122℃
• Appearance: /
• Density: 1.003
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: 2-8°C
• PKA: 10.22±0.10(Predicted)
• CAS DataBase Reference: 4-(4-METHOXYPHENYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHOXYPHENYL)PIPERIDINE(67259-62-5)
• EPA Substance Registry System: 4-(4-METHOXYPHENYL)PIPERIDINE(67259-62-5)

Safety Data

• Hazardous Substances Data: 67259-62-5(Hazardous Substances Data)

Usage

General Description

4-(4-Methoxyphenyl)piperidine is a chemical compound with the molecular formula C15H21NO. It is a piperidine derivative, containing a piperidine ring with a 4-methoxyphenyl group attached to it. 4-(4-Methoxyphenyl)piperidine has been studied for its potential pharmacological properties, including its potential as a ligand for various receptors and enzymes. It is also of interest for its potential use in medicinal chemistry and drug development. Further research is needed to fully understand the biological and pharmacological effects of 4-(4-Methoxyphenyl)piperidine and its potential applications.

InChI:InChI=1/C12H17NO/c1-14-12-4-2-10(3-5-12)11-6-8-13-9-7-11/h2-5,11,13H,6-9H2,1H3

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 303975-71-5 tert-butyl 4-(4-methoxyphenyl)piperidine-1-carboxylate 
• 149377-19-5 4-(4-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 286961-23-7 benzyl 4-(4-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 127625-95-0 benzyl 4-(4-methoxyphenyl)piperidine-1-carboxylate 
• 75-34-3 1,1-dichloroethane 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 286961-15-7 benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1 (2H)-pyridinecarboxylate 
• 286961-24-8 benzyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulphonyloxy)-pyridine-1-carboxylate 

Downstream Products

• 474710-95-7 6-bromo-4-[4-(4-methoxyphenyl)piperidin-1-yl]quinazoline 
• 946429-26-1 1-methoxymethyl-4-(4-methoxy-phenyl)-piperidine 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2Receptor Complex

We report the synthesis of the first series of heterobivalent ligands targeting the putative heteromeric 5-HT2A/mGlu2 receptor complex, based on the 5-HT2A antagonist MDL-100,907 and the mGlu2 ago-PAM JNJ-42491293. The functional properties of monovalent and heterobivalent ligands were characterized in 5-HT2A-, mGlu2/Gqo5-, 5-HT2A/mGlu2-, and 5-HT2A/mGlu2/Gqo5-expressing HEK293 cells using a Ca2+ imaging assay and a [3H]ketanserin binding assay. Pronounced functional crosstalk was observed between the two receptors in 5-HT2A/mGlu2 and 5-HT2A/mGlu2/Gqo5 cells. While the synthesized monovalent ligands retained the 5-HT2A antagonist and mGlu2 ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-HT2A/mGlu2 cells and both 5-HT- and Glu-induced responses in 5-HT2A/mGlu2/Gqo5 cells. However, no definitive correlation between the functional potency and spacer length of the ligands was observed, an observation substantiated by the binding affinities exhibited by the compounds in 5-HT2A, 5-HT2A/mGlu2, and 5-HT2A/mGlu2/Gqo5 cells. In conclusion, while functional crosstalk between 5-HT2A and mGlu2 was demonstrated, it remains unclear how these heterobivalent ligands interact with the putative receptor complex.

Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents

Accumulating evidence has shown multiple roles that chemokine receptor CCR5 may play to promote the progression of several types of cancer. The mechanism of such promotion is believed to involve chronic inflammation that creates a microenvironment which e

Heterocyclic compounds for the treatment of CNS and cardiovascular disorders

Novel aromatic bicyclic amines of formula (I) STR1 are useful in treating central nervous system disorders and cardiac arrhythmias and cardiac fibrillation.